Imunon, Inc. Gain (Loss) on Investments
Imunon, Inc. (IMNN) reported Gain (Loss) on Investments of $61.98 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Income Statement › Other Income
us-gaap:GainLossOnInvestments · last filed 2026-03-31
- Imunon, Inc. gain (loss) on investments for the quarter ending 2024-12-31 was $0.00.
- Imunon, Inc. gain (loss) on investments for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- Imunon, Inc. gain (loss) on investments for the quarter ending 2024-06-30 was $135.45K.
- Imunon, Inc. gain (loss) on investments for the quarter ending 2024-03-31 was -$73.47K.
- Imunon, Inc. gain (loss) on investments for fiscal 2024 was $61.98K.
- Imunon, Inc. gain (loss) on investments for fiscal 2023 was -$34.30K.
| Period end | Gain (Loss) on Investments 3 month | Gain (Loss) on Investments 6 month | Gain (Loss) on Investments 9 month | Gain (Loss) on Investments 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $0.00 derived: sum of 2 quarters · filed 2026-03-31 | $135.45K derived: sum of 3 quarters · filed 2026-03-31 | $61.98K 10-K · filed 2026-03-31 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $135.45K derived: sum of 2 quarters · filed 2025-11-13 | $61.98K 10-Q · filed 2025-11-13 | $21.62K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $135.45K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $61.98K 10-Q · filed 2025-08-05 | $21.62K derived: sum of 3 quarters · filed 2025-08-05 | $163.94K derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | -$73.47K 10-Q · filed 2025-05-12 | -$113.83K derived: sum of 2 quarters · filed 2025-05-12 | $28.49K derived: sum of 3 quarters · filed 2025-05-12 | -$4.68K derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | -$40.36K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $101.95K derived: sum of 2 quarters · filed 2025-02-27 | $68.78K derived: sum of 3 quarters · filed 2025-02-27 | -$34.30K 10-K · filed 2025-02-27 |
| 2023-09-30 | $142.32K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $109.14K derived: sum of 2 quarters · filed 2024-11-07 | $6.06K 10-Q · filed 2024-11-07 | |
| 2023-06-30 | -$33.17K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$136.26K 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | -$103.08K 10-Q · filed 2024-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |